Literature DB >> 27807149

Impact of High Diversity of Achromobacter Populations within Cystic Fibrosis Sputum Samples on Antimicrobial Susceptibility Testing.

Chloé Dupont1, Estelle Jumas-Bilak1,2, Anne-Laure Michon1,3, Raphaël Chiron4, Hélène Marchandin5,3.   

Abstract

Chronic colonization by opportunistic environmental bacteria is frequent in the airways of cystic fibrosis (CF) patients. Studies of Pseudomonas aeruginosa evolution during persistence have highlighted the emergence of pathoadaptive genotypes and phenotypes, leading to complex and diversified inpatient colonizing populations also observed at the intraspecimen level. Such diversity, including heterogeneity in resistance profiles, has been considered an adaptive strategy devoted to host persistence. Longitudinal genomic diversity has been shown for the emergent opportunistic pathogen Achromobacter, but phenotypic and genomic diversity has not yet been studied within a simple CF sputum sample. Here, we studied the genomic diversity and antimicrobial resistance heterogeneity of 132 Achromobacter species strains (8 to 27 strains of identical or distinct colonial morphotypes per specimen) recovered from the sputum samples of 9 chronically colonized CF patients. We highlighted the high within-sample and within-morphotype diversity of antimicrobial resistance (disk diffusion) and genomic (pulsed-field gel electrophoresis) profiles. No sputum sample included strains with identical pulsotypes or antibiotic susceptibility patterns. Differences in clinical categorization were observed for the 9 patients and concerned 3 to 11 antibiotics, including antibiotics recommended for use against Achromobacter Within-sample antimicrobial resistance heterogeneity, not predictable from colonial morphology, suggested that it may represent a selective advantage against antibiotics in an Achromobacter persisting population and potentially compromise the antibiotic management of CF airway infections.
Copyright © 2016 American Society for Microbiology.

Entities:  

Keywords:  Achromobacter; antimicrobial susceptibility; cystic fibrosis; diversity; genome

Mesh:

Year:  2016        PMID: 27807149      PMCID: PMC5228232          DOI: 10.1128/JCM.01843-16

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  34 in total

1.  Pan-Resistant Achromobacter xylosoxidans and Stenotrophomonas maltophilia Infection in Cystic Fibrosis Does Not Reduce Survival After Lung Transplantation.

Authors:  Leonard Jason Lobo; Zeynep Tulu; Robert M Aris; Peadar G Noone
Journal:  Transplantation       Date:  2015-10       Impact factor: 4.939

2.  Achromobacter xylosoxidans infection in an adult cystic fibrosis unit in Madrid.

Authors:  Laura Llorca Otero; Rosa Girón Moreno; Buenaventura Buendía Moreno; Claudia Valenzuela; Alba Guiu Martínez; Teresa Alarcón Cavero
Journal:  Enferm Infecc Microbiol Clin       Date:  2015-06-29       Impact factor: 1.731

3.  Pseudomonas aeruginosa population diversity and turnover in cystic fibrosis chronic infections.

Authors:  Eilidh Mowat; Steve Paterson; Joanne L Fothergill; Elli A Wright; Martin J Ledson; Martin J Walshaw; Michael A Brockhurst; Craig Winstanley
Journal:  Am J Respir Crit Care Med       Date:  2011-02-04       Impact factor: 21.405

Review 4.  Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis.

Authors:  Christopher H Goss; Jane L Burns
Journal:  Thorax       Date:  2007-04       Impact factor: 9.139

Review 5.  Adaptation of Pseudomonas aeruginosa during persistence in the cystic fibrosis lung.

Authors:  Michael Hogardt; Jürgen Heesemann
Journal:  Int J Med Microbiol       Date:  2010-10-12       Impact factor: 3.473

6.  Direct antimicrobial susceptibility testing method for analysis of sputum collected from patients with cystic fibrosis.

Authors:  Mohamed Zebouh; Caroline Thomas; Patrick Honderlick; Ludovic Lemee; Christine Segonds; Frédéric Wallet; Marie-Odile Husson
Journal:  J Cyst Fibros       Date:  2008-02-20       Impact factor: 5.482

7.  Instantaneous within-patient diversity of Pseudomonas aeruginosa quorum-sensing populations from cystic fibrosis lung infections.

Authors:  Cara N Wilder; Gopal Allada; Martin Schuster
Journal:  Infect Immun       Date:  2009-10-05       Impact factor: 3.441

8.  Epidemiology and resistance of Achromobacter xylosoxidans from cystic fibrosis patients in Dijon, Burgundy: first French data.

Authors:  Lucie Amoureux; Julien Bador; Eliane Siebor; Nathalie Taillefumier; Annlyse Fanton; Catherine Neuwirth
Journal:  J Cyst Fibros       Date:  2012-09-01       Impact factor: 5.482

Review 9.  Emerging cystic fibrosis pathogens and the microbiome.

Authors:  Eshwar Mahenthiralingam
Journal:  Paediatr Respir Rev       Date:  2014-04-13       Impact factor: 2.726

10.  Phenotypic diversity within a Pseudomonas aeruginosa population infecting an adult with cystic fibrosis.

Authors:  Shawn T Clark; Julio Diaz Caballero; Mary Cheang; Bryan Coburn; Pauline W Wang; Sylva L Donaldson; Yu Zhang; Mingyao Liu; Shaf Keshavjee; Yvonne C W Yau; Valerie J Waters; D Elizabeth Tullis; David S Guttman; David M Hwang
Journal:  Sci Rep       Date:  2015-06-05       Impact factor: 4.379

View more
  5 in total

1.  Chronic Airway Colonization by Achromobacter xylosoxidans in Cystic Fibrosis Patients Is Not Sustained by Their Domestic Environment.

Authors:  Chloé Dupont; Estelle Jumas-Bilak; Clara Doisy; Fabien Aujoulat; Raphaël Chiron; Hélène Marchandin
Journal:  Appl Environ Microbiol       Date:  2018-11-15       Impact factor: 4.792

2.  In-Host Emergence of Linezolid Resistance in a Complex Pattern of Toxic Shock Syndrome Toxin-1-Positive Methicillin-Resistant Staphylococcus aureus Colonization in Siblings with Cystic Fibrosis.

Authors:  Agathe Boudet; Alexandre Jay; Catherine Dunyach-Remy; Raphaël Chiron; Jean-Philippe Lavigne; Hélène Marchandin
Journal:  Toxins (Basel)       Date:  2021-04-28       Impact factor: 4.546

3.  Proteomic identification of Axc, a novel beta-lactamase with carbapenemase activity in a meropenem-resistant clinical isolate of Achromobacter xylosoxidans.

Authors:  Frank Fleurbaaij; Alex A Henneman; Jeroen Corver; Cornelis W Knetsch; Wiep Klaas Smits; Sjoerd T Nauta; Martin Giera; Irina Dragan; Nitin Kumar; Trevor D Lawley; Aswin Verhoeven; Hans C van Leeuwen; Ed J Kuijper; Paul J Hensbergen
Journal:  Sci Rep       Date:  2018-05-25       Impact factor: 4.379

4.  Role of Efflux in Antibiotic Resistance of Achromobacter xylosoxidans and Achromobacter insuavis Isolates From Patients With Cystic Fibrosis.

Authors:  Hussein Chalhoub; Stefanie Kampmeier; Barbara C Kahl; Françoise Van Bambeke
Journal:  Front Microbiol       Date:  2022-03-28       Impact factor: 5.640

5.  Achromobacter spp. Adaptation in Cystic Fibrosis Infection and Candidate Biomarkers of Antimicrobial Resistance.

Authors:  Angela Sandri; Laura Veschetti; Giulia Maria Saitta; Rebeca Passarelli Mantovani; Maria Carelli; Gloria Burlacchini; Sara Preato; Claudio Sorio; Paola Melotti; Anna Lisa Montemari; Ersilia V Fiscarelli; Cristina Patuzzo; Caterina Signoretto; Marzia Boaretti; Maria M Lleò; Giovanni Malerba
Journal:  Int J Mol Sci       Date:  2022-08-17       Impact factor: 6.208

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.